44 results about "Ribonucleotide reductase" patented technology

Novel DNA constructs and host cells comprising the same are disclosed. DNA constructs comprise a transcription unit (e.g. operon) comprising DNA sequences encoding for ribonucleotide reductase and thioredoxin. In preferred embodiments, constructs further comprise DNA sequences encoding for thymidylate synthase and/or transcription units comprising sequences encoding for uridine kinase preferably together with dCTP deaminase. In particularly preferred embodiments, host cells comprising constructs having all of the above characteristics wherein the host cell displays repressed or no uracil DNA glycosylase activity. This may be achieved by removal of the host cell ung gene. Use of host cells in the manufacture of pyrimidine deoxyribonucleotides e.g. thymidine is also disclosed.

The invention discloses a rice protein capable of promoting chloroplast development and a coding gene and application thereof. The protein is one of 1) a protein formed by amino acid residue sequences of the SEQ ID No.2 in a sequence table or 2) a protein which is formed after one or more amino acid residues in the amino acid residue sequences of the SEQ ID No.2 in the sequence table are substituted and/or deleted and/or added and has the same activities as the amino acid residue sequences of the SEQ ID No.2. The gene is used for coding the small subunit of ribonucleotide reductase, and the development of rice chloroplast is affected after the gene is mutated so that white stripes are distributed on the rice leaves in the vein direction.

The mechanism of action of Ebselen differentiates between bacterial and mammalian thioredoxin reductase (TrxR). It displays fast oxidation of mammalian Trx and via the NADPH-TrxR catalyzed turnover of ebselen selenol with hydrogen peroxide, and therefore are mammalian antioxidants. Ebselen, and its diselenide, are strong competitive inhibitors of E. coli TrxR with K_i of 0.14 μM and 0.46 μM, respectively. E. coli mutants lacking glutathione reductase or glutathione were much more sensitive to inhibition by ebselen. Since either glutaredoxin or thioredoxin systems are electron donors to ribonucleotide reductase, ebselen targets primarily glutathione and glutaredoxin-negative bacteria, a class which includes major pathogens. Ebselen, and similar compounds are therefore useful as antibacterial agents, even for multiresistant strains. Two major pathogenic bacteria, which previously had not been known to be sensitive to ebselen, Mycobacterium tuberculosis (tuberculosis) and Helicobacter pylori (stomach ulcer and cancer), were shown to be excellent targets. Helicobacter pylori was also sensitive to ebsulfur.

The invention provides new application of 4-hydroxy salicylanilide in the field of pharmacy. 4-hydroxy salicylanilide is an inhibitor of ribonucleotide reductase (RR) and inhibits the enzyme activity of RR, so that the compounding of dNTPs required by reproduction of HBV is blocked, and the aims of inhibiting reproduction of HBV, treating hepatitis and particularly treating hepatitis B are fulfilled. The 4-hydroxy salicylanilide can be used for preventing and treating the hepatitis B and has a significant application prospect.

The present invention provides antisense oligonucleotides directed to a mammalian ribonucleotide reductase R2 gene and combinations of the antisense oligonucleotides with one or more chemotherapeutic agents for use in the treatment of cancer.

Novel DNA constructs and host cells comprising the same are disclosed. DNA constructs comprise a transcription unit (e.g. operon) comprising DNA sequences encoding for ribonucleotide reductase and thioredoxin or a uridine kinase gene and/or a dCTP deaminase gene. In preferred embodiments the constructs comprising DNA sequences encoding for ribonucleotide reductase and thioredoxin further comprise DNA sequences encoding for thymidylate synthase and/or transcription units comprising sequences encoding for uridine kinase preferably together with dCTP deaminase. In particularly preferred embodiments, the host cells comprise constructs having all of the above characteristics wherein the host cell displays repressed or no uracil DNA glycosylase activity. This may be achieved by removal of the host cell ung gene. Use of host cells in the manufacture of pyrimidine deoxyribonucleotides e.g. thymidine is also disclosed.

Various genes of herpes virus of turkeys (HVT), Marek's disease virus (MDV) and infectious laryngotracheitis virus (ILTV) have been identified as non-essential regions (and candidates for insertion sites for foreign genes) and/or as antigen-encoding regions. The former include the HVT homologue of the HSV (herpes simplex virus) gC gene, the TX (thymidine kinase) region of MDV or ILTV, ORF3 of ILTV (as defined herein), the ribonucleotide reductase (large subunit) gene of ILTV, MDV or HVT and the ribonucleotide reductase (small subunit) gene of MDV. The antigen-encoding regions include the HVT homologues of the HSV gB, gC and gH genes, the ILTV homologue of HSV gB, ORF2 of ILTV, and the HVT homologue of the HSV-1 immediate early genes IE-175 and IE-68. Manipulation of these genes allows vaccines to be prepared comprising attenuated virus or virus carrying heterologous antigen-encoding sequences.

The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient.

A compound represented by Formula (I) [wherein, X¹ represents an oxygen atom or the like; X² represents an oxygen atom; X³ represents —NH—; X⁴ represents a hydrogen atom or the like; R¹ represents —C(R¹¹)(R¹²)— or the like; R¹¹ and R¹² are the same or different and each represents a hydrogen atom or the like; R² represents an optionally substituted C⁶-C¹⁴ aromatic hydrocarbon group or the like; R³ represents an optionally substituted C⁶-C¹⁴ aromatic hydrocarbon group or the like; R⁴ represents a hydrogen atom or the like] or a salt thereof.

The invention discloses application of RRM2B gene or protein thereof in metastasis of hepatocellular carcinoma, and particularly provides application of detection reagents of ribonucleoside-diphosphate reductase subunit M2B (RRM2B) gene or protein thereof, as well as the RRM2B gene or protein thereof for preparing kits for diagnosing metastasis of hepatocellular carcinoma. Furthermore, the RRM2B has an inhibiting effect on metastasis of hepatocellular carcinoma, and a new approach is provided to diagnosis and treatment of metastasis of hepatocellular carcinoma.

The invention provides a method for quantitatively detecting the relative expression quantity of RRM1 (ribonucleotide reductase M1) mRNA (messenger ribonucleic acid) in a sample. In the method, the relative expression quantity of RRM1mRNA in the sample can be quantitatively detected by use of the real-time fluorescence quantification PCR (polymerase chain reaction) technology. The invention provides a primer and a probe for quantitatively detecting the relative expression quantity of RRM1 mRNA in the sample, wherein the primer and the probe comprise upstream and downstream primers RRM1-F/RRM1-R and a probe RRM1-Probe for detection as well as upstream and downstream primers Actin-F/Actin-R and a probe Actin-Probe for a house-keeping gene actin. The invention also provides a kit for quantitatively detecting the relative expression quantity of RRM1 mRNA in the sample. By calculating the ratio of the expression quantity of RRM1 in the sample obtained by the method to the normal base of a healthy person, obtained by statistics, the relative expression quantity of RRM1 mRNA is obtained, the detection time can be effectively saved, and the detection accuracy is improved.

The invention relates to a target spot selecting method for efficiently inhibiting WSSV (White Spot Syndrome Virus), which comprises the steps of: 1, selecting coded sequences of ribonucleotide reductase and DNA polymerase in a WSSV genome; 2, generating a WSSV-resistant small RNA interference molecule by using software; and 3, screening theoretically efficient WSSV-resistant siRNA (small interfering RNA) according to a siRNA design rule. The small RNA molecule is designed by using the target spot selecting method, thus the selection range of the virus-resistant small RNA molecule can be effectively narrowed, the working efficiency is increased, the research cost is remarkably lowered, and the popularization and the application of an RNA interference technology in the aquatic virus-resistant field are facilitated.

The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient.

A compound represented by Formula (I) [wherein, X¹ represents an oxygen atom or the like; X² represents an oxygen atom; X³ represents —NH—; X⁴ represents a hydrogen atom or the like; R¹ represents —C(R¹¹)(R¹²)— or the like; R¹¹ and R¹² are the same or different and each represents a hydrogen atom or the like; R² represents an optionally substituted C⁶-C¹⁴ aromatic hydrocarbon group or the like; R³ represents an optionally substituted C⁶-C¹⁴ aromatic hydrocarbon group or the like; R⁴ represents a hydrogen atom or the like] or a salt thereof.

The invention relates to ribonucleotide reductase from 'Bailing' producing strain cordyceps sinensis hirsutella sinensis for anabolism of deoxidized pyrimidine nucleoside diphosphate from pyrimidine nucleoside diphosphate, a gene coding the ribonucleotide reductase and application of the ribonucleotide reductase. The ribonucleotide reductase has over 90% of homology to the amino acid sequence shown by SEQ ID No.1 or SEQ ID No.3; and the coding gene has over 90% of homology to the nucleotide sequence shown by SEQ ID No.2 or SEQ ID No.4. According to the invention, the metabolic pathway for synthesizing deoxidized pyrimidine nucleoside diphosphate from pyrimidine nucleoside diphosphate is studied in details in principle, the cloning DNA (Deoxyribonucleic Acid) comprising the nucleotide sequence provided by the invention can be transferred into engineering bacteria through transduction, transformation and combined transfer, high expressivity of the host deoxidized pyrimidine nucleoside diphosphate is obtained by adjusting the expression of the deoxidized pyrimidine nucleoside diphosphate biosynthesis gene, an effective means of increasing output of the deoxidized pyrimidine nucleoside diphosphate is provided, and a significant application prospect is realized.

The invention discloses a synthetic method of beta-thymidine. Thymidine is synthesized reversely by adopting enzyme engineering, glucose dehydrogenase, uridine kinase, inkfish pyruvate kinase, ribonucleotide reductase, thymidylate kinase and thymidine kinase are used, 5-methyluridine is used as a raw material, nucleotide is generated through two phosphorylation steps and then is converted into deoxynucleotide, and then the thymidine is generated through two-step dephosphorylation. According to the synthetic method of beta-thymidine disclosed by the invention, the cost is greatly reduced, the production cycle is shortened, the industrial waste is reduced, and the beta-thymidine is non-toxic and environmentally-friendly.

The present invention provides a method of enhancing an antitumor effect by a compound strongly inhibiting ribonucleotide reductase (RNR) or a salt thereof.

A combination formulation involving combined administration of a sulfonamide compound represented by Formula (I) [In the formula, X¹ represents an oxygen atom or the like; X² represents an oxygen atom; X³ represents —NH—; X⁴ represents a hydrogen atom or the like; R¹ represents —C(R¹¹) (R¹²)— or the like; R¹¹ and R¹² are the same or different and each represents a hydrogen atom or the like; R² represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R³ represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R⁴ represents a hydrogen atom or the like] or a salt thereof, having RNR inhibitory activity, and other antitumor agent(s).

The present invention relates to compositions comprising HSV antigens and methods for their use in the treatment or prevention of asymptomatic and symptomatic herpesvirus infection, or recurrence.